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Abstract
Prior to the discovery of medical treatment for diabetes, carbohydrate-restriction was the
predominant treatment recommendation to treat diabetes mellitus. In this commentary we argue
that carbohydrate-restriction should be reincorporated into contemporary treatment studies for
diabetes mellitus.
Introduction
In the early 20th century, before any medications were
available for the treatment of diabetes mellitus, experts
recommended dietary carbohydrate-restriction [1,2]. The
dietary recommendation for diabetes in a prominent
internal medicine textbook from 1923 was 75% fat, 17%
protein, 6% alcohol and only 2% carbohydrate [3]. The
recommended total daily energy intake was 1,795 Calo-
ries per day. After the discovery of insulin and oral
hypoglycemic medications, experts gradually changed the
dietary recommendations to include more carbohydrate
intake because most experts reasoned that the medica-
tions could be used to keep the glucose in control.
The NIH NHLBI Action to Control Cardiovascular Risk in
Diabetes (ACCORD) group recently announced termina-
tion of the intensive insulin therapy arm of their study
after an interim analysis showed that mortality was signif-
icantly higher in this group than in the other two less
intensive glucose control groups [4,5]. Because lead inves-
tigators from the ACCORD trial and other experts have
stated how unexpected this finding was, and have sug-
gested that the concept of normal glucose control among
patients with type 2 diabetes may not be desirable, we feel
compelled to provide an alternative view.
Discussion
From our perspective of familiarity with dietary carbohy-
drate-restriction and diabetes, these results are not surpris-
ing–in fact, they are predicted. We believe that it is
unlikely that the increased mortality was due to the tight
glucose control but rather due to the particular method
for trying to achieve it. When high carbohydrate diets are
consumed and intensive medication therapy is used to
"cover the carbohydrate," it is very difficult to achieve nor-
mal glycemic control without hypoglycemic reactions. In our
clinical practices, we frequently see individuals who are
instructed to eat high carbohydrate diets and use intensive
injectable hypoglycemic therapy, and they are susceptible
to hypoglycemic reactions. Severe hypoglycemic reactions
are associated with an increased morbidity and mortality
[6].
There are other ways to improve glycemic control without
the risk of hypoglycemic reactions; one of these is carbo-
hydrate-restriction. Carbohydrate-restriction makes
pathophysiological sense because type 2 diabetes is, in
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essence, a case of carbohydrate intolerance. We have
observed that the same patients who have hypoglycemic
reactions with high carbohydrate diets and aggressive
medication therapy no longer have hypoglycemic reac-
tions with carbohydrate-restriction. Moreover, the contin-
ued concerns about carbohydrate-restricted diets have
never materialized and recent scientific studies show gen-
eral health benefits including reduced cardiometabolic
risk factors [7-10].
Based on the clinical experience of others, and published
clinical trials, we use carbohydrate-restriction in clinical
practice for the treatment of diabetes mellitus [11-15]. At
the end of our clinic day, we go home thinking, "The clin-
ical improvements are so large and obvious, why don't
other doctors understand?" Carbohydrate-restriction is
easily grasped by patients: because carbohydrates in the
diet raise the blood glucose, and as diabetes is defined by
high blood glucose, it makes sense to lower the carbohy-
drate in the diet. By reducing the carbohydrate in the diet,
we have been able to taper patients off as much as 150
units of insulin per day in 8 days, with marked improve-
ment in glycemic control-even normalization of glycemic
parameters. Due to the potent effect of carbohydrate
restriction in decreasing blood glucose levels, we must
reduce the insulin by 50% on the first day of dietary car-
bohydrate-restriction to avoid hypoglycemia. As the
weeks pass, most patients achieve normoglycemia with-
out medication, obese patients lose weight, and patients
save money because they are not paying for medications.
It is not so far-fetched to predict that these savings will
also be passed along to the health care system and self-
insured companies because there will be less expenditure
on medications and the long-term diabetic complications.
Conclusion
The inattention to potent  dietary therapy in all recent
major diabetes studies, including the recent ACCORD
trial, should not lead us to forget about carbohydrate-
restriction as a means to achieve weight loss and glycemic
control without hypoglycemia. We urgently need control-
led studies comparing the newer "higher-carbohydrate
diet with or without medication" approach to the earlier
"carbohydrate-restricted diet without medication"
approach for type 2 diabetes mellitus. One of the impor-
tant advantages of carbohydrate-restriction is that there is
no risk of hypoglycemia if medications are not used. We
believe that carbohydrate-restriction has come of age for
the treatment of obesity and diabetes mellitus and should
be urgently translated from clinical practice to intensive
testing in studies relating to mechanism, health services
research, and public health.
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